honor roll of donors - UCSF Helen Diller Family Comprehensive

financial highlights
Visionary Circle
Honor Roll
of Donors
Lifetime Giving of $1 Million and Above
Restricted
$27,754,549
7.1%
e.g., to a specific program
Unrestricted
$2,115,236
92.9%
e.g., General Fund
Total$29,869,785
1%
Sources of Philanthropic Support
To cancer programs at UCSF for the fiscal year
ending June 30, 2013
Individuals
$15,935,803
Foundations and
Family Foundations
Corporations
15%
Other Organizations
$9,198,295
53%
31%
$4,559,126
$176,561
Total$29,869,785
Sources of
Philanthropic Support
$45,828,912
$42,437,012
$36,491,451
Yearly summary for fiscal years 2009–2013
$31,913,032
$29,869,785
Other Organizations
Individuals
Foundations and Family Foundations
Corporations
2009
2010
2011
2012
2013
Anonymous (18)
Accelerate Brain Cancer Cure, Inc.
The Bonnie J. Addario Lung
Cancer Foundation
Estate of Edward S. Ageno
American Association for
Cancer Research
American Brain Tumor Association
American Cancer Society
American Cancer Society
California Division
American Society of Clinical Oncology
Estate of Stanford W. Ascherman
The Atlantic Philanthropies
Martha and H. Brewster Atwater
Roma M. Auerback
Avon Foundation
Ayco Charitable Foundation
Lynne and Marc R. Benioff
Theodora B. Betz Foundation
Bionovo, Inc.
Jane Bishop *
Frances F. Bowes
William K. Bowes, Jr. Foundation
The Breast Cancer Research
Foundation
Linda and Neill H. Brownstein
Carol Franc Buck
Eva Benson Buck Charitable Trust D
Estate of Hildur V. Bullerwell
Christine and Steven A. Burd
Frank A. Campini Foundation
Cancer Research Institute
Champion Charities
Chevron U.S.A. Inc.
Estate of Ruth M. DeBernardi
Donna M. and Kenneth T. Derr
Helen Diller Family Foundation
Ann H. and L. John Doerr III
Estate of Volker Dolch
Carol P. and Michael I. Dollinger
The Dougherty Family Foundation
Greg Dougherty
Nancy Dougherty
Joseph Drown Foundation
The Ellison Medical Foundation
Anne and Jason Farber
Foundation, Inc.
Estate of Condina J. Ferro
Fidelity Investments Charitable
Gift Fund
Fisher Families
Joseph H. Friend *
Susan M. Geck *
Genentech, Inc.
The Goldhirsh Foundation, Inc.
Richard and Rhoda Goldman Fund
Richard N. Goldman *
Nancy and Stephen Grand
Guzik Foundation
Mimi and Peter Haas Fund
Estate of E. Dixon Heise
Informed Medical Decisions
Foundation
Pepper and Michael Jackson
Joan and Irwin M. Jacobs
Jewish Community Federation of
San Francisco, the Peninsula,
Marin and Sonoma Counties
Jewish Community Foundation
Jewish Community Foundation
of San Diego
Kalmanovitz Charitable Foundation
Kazan, McClain, Abrams,
Fernandez, Lyons, Greenwood, Harley & Oberman Foundation
Kirk Kerkorian
Alison and Arthur H. Kern
Gwen M. and John A. Kerner
Sidney Kimmel Foundation for
Cancer Research
The Susan G. Komen Breast
Cancer Foundation
Deepa N. Iyengar and
Ashok Krishnamurthi
Mary V. Lester and W. Howard Lester *
The Leukemia and Lymphoma
Society
The Lincy Foundation
The Listwin Family Foundation
Edmund & Jeannik Littlefield
Foundation
Jeannik Mequet Littlefield *
Marin Community Foundation
Lucille P. Markey Charitable Trust
Estate of Alicia McEvoy
Estate of Claire C. McEvoy
Estate of Jay D. McEvoy
Nan Tucker McEvoy
Nion T. McEvoy
The Minneapolis Foundation
Estate of Frederick S. Moody
Betty I. and Gordon E. Moore
Mount Zion Health Fund
Multiple Myeloma Research
Foundation
National Brain Tumor Society
Merillyn J. Noren
Susan and William E. Oberndorf
The Bernard Osher Foundation
Pediatric Brain Tumor Foundation
Jeffrey and Karen Peterson
Family Foundation
Estate of Kathleen Mahoney Plant
Catherine H. and Michael H. Podell
Helen* and Sol* Price
Prospect Creek Foundation
Prostate Cancer Foundation
Radiology Research and
Education Foundation
Estate of Mary Ann Radovich
George R. Roberts
Estate of Mario J. Rocca
Arthur and Toni Rembe Rock
Rombauer Family
Damon Runyon Cancer
Research Foundation
The Safeway Foundation
Safeway, Inc.
The San Francisco Foundation
San Francisco General
Hospital Foundation
Schwab Charitable Fund
Bernard Lee Schwartz
Foundation, Inc.
Estate of Jack Douglas Shand
William Siebrandt
Silicon Valley Community Foundation
Sandra Lloyd and W. Douglass Smith
Elle and Paul H. Stephens
Alexander and Margaret
Stewart Trust
The V Foundation for
Cancer Research
Eddi and Wendell Van Auken
Vanguard Charitable
Endowment Program
Angela C. Wang
Dana A. Corvin and Harris Weinberg
Robert K. Werbe *
Diana S. * and Herschel S. *
Zackheim
*deceased
2012–2013
Address service requested
To cancer programs at UCSF for the fiscal year
ending June 30, 2013
0906
University Development and Alumni Relations
UCSF Box 0248
San Francisco, CA 94143-0248
Allocation of Philanthropic Support
Possibilities for Partnership
To learn more about our cancer center priorities, please contact:
Suzanne Teer, Executive Director of Development
415/476-3622
[email protected]
UCSF Box 0248, San Francisco, CA 94143-0248
support.ucsf.edu
Produced by the UCSF Office of University Development and Alumni Relations
Managing Editor: Kate Volkman Oakes Design: Pamela Kato
Writers: Jason Bardi, Elizabeth Fernandez, Susan Godstone, Photographers: Steve Babuljak, Noah Berger, Cindy Chew,
Samantha Jang, Kate Volkman Oakes Elisabeth Fall, Susan Godstone, Carmen Holt
© 2013 The Regents of the University of California
We’ve Gone Green!
Please visit us online to view a complete list of FY12-13 donors: support.ucsf.edu/cancer/honor-roll
Year in Review
your gifts, our thanks
Top Accomplishments
SUPPORTING BREAST CANCER RESEARCH
Genetic Answers to Lymphedema
Dear Friends,
UCSF researchers have found an association between certain genes and the
development of lymphedema, a painful condition that often occurs after breast cancer
surgery and some other cancer treatments. “These genes are ‘turned on’ later in the
development of our lymph system and blood vessels,” says Bradley Aouizerat, PhD,
professor in the School of Nursing and co-leader of the study. “They appear to play
a role in the ability of our lymphatic system to function on an ongoing basis. In some
individuals who have changes in these genes it’s possible that lymphedema could
develop after an injury like breast cancer surgery.” Lymphedema is the buildup of fluid in
the lymphatic tissues and can be debilitating, causing scarring, discomfort, and difficulty
in walking or other activities. Up to 56 percent of women who undergo breast cancer
surgery develop lymphedema within two years. Researchers hope to identify women at
risk for the condition and initiate measures to prevent its development.
After 17 years as director of the UCSF Helen Diller Family Comprehensive Cancer
Center, it’s time for me to focus full time on my research. I will pursue investigations both in
my lab at UCSF and as director of a new National Cancer Institute (NCI)-funded project in
Frederick, Maryland.
As I prepare to pass the torch to my yet-to-be-named successor, I can’t help but
reflect on my many rewarding experiences as director.
I came to UC San Francisco in 1996 to lead the Cancer Research Institute and quickly
set up shop to consolidate UCSF’s various cancer programs into a comprehensive cancer
center. In 1998 we received our first NCI cancer center support grant and became, for the
first time, an NCI-designated comprehensive cancer center.
My first act as head of the new center was to recruit an additional batch of brilliant
minds in basic research, clinical research, and population sciences. Together we elevated
the quality of investigations, and developed robust clinical trials and informatics programs.
Fifteen years later we are one of the top cancer centers in the country, as well as the largest
and best funded center in California.
Simultaneous to building up all these outstanding cancer programs, we built the UCSF
Helen Diller Family Cancer Research Building. The facility has been a boon to our work. Our
scientists are thriving among the powerhouse research community at Mission Bay, and our
clinicians look forward to the opening of the new cancer hospital a couple blocks away.
But one of my most gratifying experiences has been getting to know you, our donors
who believe in our mission. I’d especially like to thank the Diller family for your extraordinary
legacy of support. I also offer heartfelt thanks to Cathy Podell and Nanci Fredkin – the
organizers of our fundraising gala, Raising Hope, which began in 1996 – and to The
Atlantic Philanthropies for your loyalty to our center. And I extend my deep gratitude to
Barbara and Gerson Bakar. I am delighted that the new cancer hospital at Mission Bay will
be named the UCSF Bakar Cancer Hospital in honor of your longstanding commitment to
cancer research and care.
I sign off with a special thanks to all of you for your constant support and for continuing
to push the boundaries of our imagination. As the new director takes the reins, I trust that
your loyalty will remain steadfast.
Changing the Standard of Care
UCSF clinicians who ran a Phase 2 clinical trial testing a new protocol for treating a
relatively rare form of brain cancer, primary CNS lymphoma, say the results may
change the standard of care for the disease. Patients received a combination of highdose chemotherapy with immune therapy, rather than the standard combination of
chemotherapy with whole-brain radiotherapy. The new approach was less toxic and
worked better, with the majority of patients still alive five years following treatment. The
lymphoma-free survival of patients with this form of cancer was doubled compared to
the lymphoma-free survival in previous trials involving brain radiotherapy, says UCSF
oncologist James Rubenstein, MD, PhD, who led the study. He and his team also found a
gene that, depending on how much of it is present, is a biomarker for potentially predicting
treatment outcomes – a discovery that may enable personalized care.
Harold Varmus and J. Michael Bishop win
the Nobel Prize for their discovery of
cancer-causing oncogenes
Nancy White Gamble’s life changed in 2008, when she was diagnosed with acute promyelocytic
leukemia, a rare form of blood cancer. Within days, Gamble, who lives in Napa, Calif., met with
UCSF’s Lloyd Damon, MD, director of hematologic malignancies and bone marrow transplant.
Although the treatment that followed was harrowing, Gamble survived. In remission five years
later, she attributes much of her survival not only to the excellent care she received at UCSF,
but also to the hope Damon instilled in her. “He threw me a life preserver,” Gamble recalls,
“and all I had to do was grab it.” To show her gratitude, Gamble made a pledge to create the
Nancy White Gamble Hematologic-Malignancies Endowment. The endowment will support an
annual fellowship for future Bone Marrow Transplantation (BMT) physicians. Training the next
generation is critical, says Damon, who holds the Robert O. and Angela W. Johnson Endowed
Chair of Hematopoetic Malignancies. While the need for BMT continues to grow, the number of
doctors entering the field has not. The endowment will provide much-needed funding to help
reverse this trend.
Researchers have discovered that melanoma cells that develop resistance to the
anti-cancer drug vemurafenib (marketed as Zelboraf) also develop addiction to
the drug – an observation with potential implications for patients with late-stage
disease. The team, based at UCSF, the Novartis Institutes for Biomedical Research
in Emeryville, Calif., and University Hospital Zurich, found that as a result of their
addiction, cells use vemurafenib to spur the growth of rapidly progressing, deadly, and
drug-resistant tumors. However, adjusting the dosing and introducing an on-again,
off-again treatment schedule prolonged the life of mice with melanoma, says co-lead
researcher Martin McMahon, PhD, the Efim Guzik Distinguished Professor of Cancer
Biology. A similar approach may extend the effectiveness of the drug for people – an
idea that awaits testing in clinical trials. Melanoma is the most aggressive type of skin
cancer. In 2012 alone, an estimated 76,250 people in the US were newly diagnosed with
it, while 9,180 people died from the disease.
Director, UCSF Helen Diller Family Comprehensive Cancer Center
E. Dixon Heise Distinguished Professor in Oncology
David A. Wood Distinguished Professor of Tumor Biology and Cancer Research
Cancer Center
Milestones
Blood Cancer LifeLine Flows Both Ways
Lloyd Damon with Nancy White Gamble
Interrupting Treatment Prolongs Life
Frank McCormick, PhD, FRS, DSc (Hon)
1989
Mark Moasser
(left) with
Sisi and Bert Damner
Diagnosed with breast cancer in 2010, Sisi Damner interviewed many physicians before she
found Mark M. Moasser, MD, a breast care specialist at the UCSF Carol Franc Buck Breast
Care Center. “He’s an authority in his field and he’s also a good listener,” Damner says. “The
two don’t always go together.” Moasser is one of several UCSF physician-scientists working
at the interface of the clinical and scientific realms. He credits the patients he cares for in the
oncology clinic for motivating his research. “Our larger vision is to find curative therapies
for cancers driven by the HER2/neu oncogene, which account for 20 to 25 percent of breast
cancers as well as many other cancers,” he says. Three years later, Damner is busy traveling
and taking up new hobbies. In gratitude, she and her husband, Bert, named the UCSF breast
cancer program a beneficiary of their charitable remainder trust. “We can’t help but want to
support UCSF’s research into breast cancer,” Damner says, “the findings from which have the
potential to make a difference to cancer patients and their families worldwide.”
1998
First became an NCI-designated
comprehensive cancer center, an honor
maintained through today
2007
Cancer Center renamed the UCSF Helen Diller Family
Comprehensive Cancer Center in tribute to the family’s
commitment to improving lives around the world
Partnering to fight brain cancer
Ashley Dabbiere is mother to four active young children, so when she noticed a creeping
forgetfulness she attributed it to “baby brain.” But a 2012 MRI revealed a tumor occupying
more than half of her brain’s frontal lobe. “My husband and I immediately started doing research
because we wanted to find the best brain surgeon in the world. We quickly settled on Dr.
Berger,” says Ashley, who lives outside Washington, DC. Mitchel Berger, MD, is the Berthold
and Belle N. Guggenhime Professor and director of the Brain Tumor Research Center at UCSF.
“The Dabbieres took ownership of the problem in a way that they could be part of the solution,”
says Berger. The couple made two unrestricted gifts toward Berger’s research, which he is
using to investigate how low grade slow-growing gliomas (the type Ashley has) evolve into high
grade fast-growing tumors. “We can’t do what Dr. Berger does,” says Alan. “What we can do
is build awareness and provide funding to help him find better cures for my wife and a lot of
people. We are glad to partner with UCSF.”
Mitch Berger (left) with
Ashley and Alan Dabbiere
2009
Helen Diller Family Cancer Research Building opens
at Mission Bay, bringing investigators into the
center of a powerful basic research community
2013
Elizabeth Blackburn wins the Nobel Prize for her codiscovery of telomeres and the enzyme telomerase,
which have implications for cancer therapies
U.S. News & World Report ranked UCSF Medical Center as
the 7th best hospital in the nation, 1st among California, and
among the top in the nation for the 8th consecutive year
2015
UCSF Bakar Cancer Hospital at
Mission Bay slated to open to patients
Year in Review
your gifts, our thanks
Top Accomplishments
SUPPORTING BREAST CANCER RESEARCH
Genetic Answers to Lymphedema
Dear Friends,
UCSF researchers have found an association between certain genes and the
development of lymphedema, a painful condition that often occurs after breast cancer
surgery and some other cancer treatments. “These genes are ‘turned on’ later in the
development of our lymph system and blood vessels,” says Bradley Aouizerat, PhD,
professor in the School of Nursing and co-leader of the study. “They appear to play
a role in the ability of our lymphatic system to function on an ongoing basis. In some
individuals who have changes in these genes it’s possible that lymphedema could
develop after an injury like breast cancer surgery.” Lymphedema is the buildup of fluid in
the lymphatic tissues and can be debilitating, causing scarring, discomfort, and difficulty
in walking or other activities. Up to 56 percent of women who undergo breast cancer
surgery develop lymphedema within two years. Researchers hope to identify women at
risk for the condition and initiate measures to prevent its development.
After 17 years as director of the UCSF Helen Diller Family Comprehensive Cancer
Center, it’s time for me to focus full time on my research. I will pursue investigations both in
my lab at UCSF and as director of a new National Cancer Institute (NCI)-funded project in
Frederick, Maryland.
As I prepare to pass the torch to my yet-to-be-named successor, I can’t help but
reflect on my many rewarding experiences as director.
I came to UC San Francisco in 1996 to lead the Cancer Research Institute and quickly
set up shop to consolidate UCSF’s various cancer programs into a comprehensive cancer
center. In 1998 we received our first NCI cancer center support grant and became, for the
first time, an NCI-designated comprehensive cancer center.
My first act as head of the new center was to recruit an additional batch of brilliant
minds in basic research, clinical research, and population sciences. Together we elevated
the quality of investigations, and developed robust clinical trials and informatics programs.
Fifteen years later we are one of the top cancer centers in the country, as well as the largest
and best funded center in California.
Simultaneous to building up all these outstanding cancer programs, we built the UCSF
Helen Diller Family Cancer Research Building. The facility has been a boon to our work. Our
scientists are thriving among the powerhouse research community at Mission Bay, and our
clinicians look forward to the opening of the new cancer hospital a couple blocks away.
But one of my most gratifying experiences has been getting to know you, our donors
who believe in our mission. I’d especially like to thank the Diller family for your extraordinary
legacy of support. I also offer heartfelt thanks to Cathy Podell and Nanci Fredkin – the
organizers of our fundraising gala, Raising Hope, which began in 1996 – and to The
Atlantic Philanthropies for your loyalty to our center. And I extend my deep gratitude to
Barbara and Gerson Bakar. I am delighted that the new cancer hospital at Mission Bay will
be named the UCSF Bakar Cancer Hospital in honor of your longstanding commitment to
cancer research and care.
I sign off with a special thanks to all of you for your constant support and for continuing
to push the boundaries of our imagination. As the new director takes the reins, I trust that
your loyalty will remain steadfast.
Changing the Standard of Care
UCSF clinicians who ran a Phase 2 clinical trial testing a new protocol for treating a
relatively rare form of brain cancer, primary CNS lymphoma, say the results may
change the standard of care for the disease. Patients received a combination of highdose chemotherapy with immune therapy, rather than the standard combination of
chemotherapy with whole-brain radiotherapy. The new approach was less toxic and
worked better, with the majority of patients still alive five years following treatment. The
lymphoma-free survival of patients with this form of cancer was doubled compared to
the lymphoma-free survival in previous trials involving brain radiotherapy, says UCSF
oncologist James Rubenstein, MD, PhD, who led the study. He and his team also found a
gene that, depending on how much of it is present, is a biomarker for potentially predicting
treatment outcomes – a discovery that may enable personalized care.
Harold Varmus and J. Michael Bishop win
the Nobel Prize for their discovery of
cancer-causing oncogenes
Nancy White Gamble’s life changed in 2008, when she was diagnosed with acute promyelocytic
leukemia, a rare form of blood cancer. Within days, Gamble, who lives in Napa, Calif., met with
UCSF’s Lloyd Damon, MD, director of hematologic malignancies and bone marrow transplant.
Although the treatment that followed was harrowing, Gamble survived. In remission five years
later, she attributes much of her survival not only to the excellent care she received at UCSF,
but also to the hope Damon instilled in her. “He threw me a life preserver,” Gamble recalls,
“and all I had to do was grab it.” To show her gratitude, Gamble made a pledge to create the
Nancy White Gamble Hematologic-Malignancies Endowment. The endowment will support an
annual fellowship for future Bone Marrow Transplantation (BMT) physicians. Training the next
generation is critical, says Damon, who holds the Robert O. and Angela W. Johnson Endowed
Chair of Hematopoetic Malignancies. While the need for BMT continues to grow, the number of
doctors entering the field has not. The endowment will provide much-needed funding to help
reverse this trend.
Researchers have discovered that melanoma cells that develop resistance to the
anti-cancer drug vemurafenib (marketed as Zelboraf) also develop addiction to
the drug – an observation with potential implications for patients with late-stage
disease. The team, based at UCSF, the Novartis Institutes for Biomedical Research
in Emeryville, Calif., and University Hospital Zurich, found that as a result of their
addiction, cells use vemurafenib to spur the growth of rapidly progressing, deadly, and
drug-resistant tumors. However, adjusting the dosing and introducing an on-again,
off-again treatment schedule prolonged the life of mice with melanoma, says co-lead
researcher Martin McMahon, PhD, the Efim Guzik Distinguished Professor of Cancer
Biology. A similar approach may extend the effectiveness of the drug for people – an
idea that awaits testing in clinical trials. Melanoma is the most aggressive type of skin
cancer. In 2012 alone, an estimated 76,250 people in the US were newly diagnosed with
it, while 9,180 people died from the disease.
Director, UCSF Helen Diller Family Comprehensive Cancer Center
E. Dixon Heise Distinguished Professor in Oncology
David A. Wood Distinguished Professor of Tumor Biology and Cancer Research
Cancer Center
Milestones
Blood Cancer LifeLine Flows Both Ways
Lloyd Damon with Nancy White Gamble
Interrupting Treatment Prolongs Life
Frank McCormick, PhD, FRS, DSc (Hon)
1989
Mark Moasser
(left) with
Sisi and Bert Damner
Diagnosed with breast cancer in 2010, Sisi Damner interviewed many physicians before she
found Mark M. Moasser, MD, a breast care specialist at the UCSF Carol Franc Buck Breast
Care Center. “He’s an authority in his field and he’s also a good listener,” Damner says. “The
two don’t always go together.” Moasser is one of several UCSF physician-scientists working
at the interface of the clinical and scientific realms. He credits the patients he cares for in the
oncology clinic for motivating his research. “Our larger vision is to find curative therapies
for cancers driven by the HER2/neu oncogene, which account for 20 to 25 percent of breast
cancers as well as many other cancers,” he says. Three years later, Damner is busy traveling
and taking up new hobbies. In gratitude, she and her husband, Bert, named the UCSF breast
cancer program a beneficiary of their charitable remainder trust. “We can’t help but want to
support UCSF’s research into breast cancer,” Damner says, “the findings from which have the
potential to make a difference to cancer patients and their families worldwide.”
1998
First became an NCI-designated
comprehensive cancer center, an honor
maintained through today
2007
Cancer Center renamed the UCSF Helen Diller Family
Comprehensive Cancer Center in tribute to the family’s
commitment to improving lives around the world
Partnering to fight brain cancer
Ashley Dabbiere is mother to four active young children, so when she noticed a creeping
forgetfulness she attributed it to “baby brain.” But a 2012 MRI revealed a tumor occupying
more than half of her brain’s frontal lobe. “My husband and I immediately started doing research
because we wanted to find the best brain surgeon in the world. We quickly settled on Dr.
Berger,” says Ashley, who lives outside Washington, DC. Mitchel Berger, MD, is the Berthold
and Belle N. Guggenhime Professor and director of the Brain Tumor Research Center at UCSF.
“The Dabbieres took ownership of the problem in a way that they could be part of the solution,”
says Berger. The couple made two unrestricted gifts toward Berger’s research, which he is
using to investigate how low grade slow-growing gliomas (the type Ashley has) evolve into high
grade fast-growing tumors. “We can’t do what Dr. Berger does,” says Alan. “What we can do
is build awareness and provide funding to help him find better cures for my wife and a lot of
people. We are glad to partner with UCSF.”
Mitch Berger (left) with
Ashley and Alan Dabbiere
2009
Helen Diller Family Cancer Research Building opens
at Mission Bay, bringing investigators into the
center of a powerful basic research community
2013
Elizabeth Blackburn wins the Nobel Prize for her codiscovery of telomeres and the enzyme telomerase,
which have implications for cancer therapies
U.S. News & World Report ranked UCSF Medical Center as
the 7th best hospital in the nation, 1st among California, and
among the top in the nation for the 8th consecutive year
2015
UCSF Bakar Cancer Hospital at
Mission Bay slated to open to patients
Year in Review
your gifts, our thanks
Top Accomplishments
SUPPORTING BREAST CANCER RESEARCH
Genetic Answers to Lymphedema
Dear Friends,
UCSF researchers have found an association between certain genes and the
development of lymphedema, a painful condition that often occurs after breast cancer
surgery and some other cancer treatments. “These genes are ‘turned on’ later in the
development of our lymph system and blood vessels,” says Bradley Aouizerat, PhD,
professor in the School of Nursing and co-leader of the study. “They appear to play
a role in the ability of our lymphatic system to function on an ongoing basis. In some
individuals who have changes in these genes it’s possible that lymphedema could
develop after an injury like breast cancer surgery.” Lymphedema is the buildup of fluid in
the lymphatic tissues and can be debilitating, causing scarring, discomfort, and difficulty
in walking or other activities. Up to 56 percent of women who undergo breast cancer
surgery develop lymphedema within two years. Researchers hope to identify women at
risk for the condition and initiate measures to prevent its development.
After 17 years as director of the UCSF Helen Diller Family Comprehensive Cancer
Center, it’s time for me to focus full time on my research. I will pursue investigations both in
my lab at UCSF and as director of a new National Cancer Institute (NCI)-funded project in
Frederick, Maryland.
As I prepare to pass the torch to my yet-to-be-named successor, I can’t help but
reflect on my many rewarding experiences as director.
I came to UC San Francisco in 1996 to lead the Cancer Research Institute and quickly
set up shop to consolidate UCSF’s various cancer programs into a comprehensive cancer
center. In 1998 we received our first NCI cancer center support grant and became, for the
first time, an NCI-designated comprehensive cancer center.
My first act as head of the new center was to recruit an additional batch of brilliant
minds in basic research, clinical research, and population sciences. Together we elevated
the quality of investigations, and developed robust clinical trials and informatics programs.
Fifteen years later we are one of the top cancer centers in the country, as well as the largest
and best funded center in California.
Simultaneous to building up all these outstanding cancer programs, we built the UCSF
Helen Diller Family Cancer Research Building. The facility has been a boon to our work. Our
scientists are thriving among the powerhouse research community at Mission Bay, and our
clinicians look forward to the opening of the new cancer hospital a couple blocks away.
But one of my most gratifying experiences has been getting to know you, our donors
who believe in our mission. I’d especially like to thank the Diller family for your extraordinary
legacy of support. I also offer heartfelt thanks to Cathy Podell and Nanci Fredkin – the
organizers of our fundraising gala, Raising Hope, which began in 1996 – and to The
Atlantic Philanthropies for your loyalty to our center. And I extend my deep gratitude to
Barbara and Gerson Bakar. I am delighted that the new cancer hospital at Mission Bay will
be named the UCSF Bakar Cancer Hospital in honor of your longstanding commitment to
cancer research and care.
I sign off with a special thanks to all of you for your constant support and for continuing
to push the boundaries of our imagination. As the new director takes the reins, I trust that
your loyalty will remain steadfast.
Changing the Standard of Care
UCSF clinicians who ran a Phase 2 clinical trial testing a new protocol for treating a
relatively rare form of brain cancer, primary CNS lymphoma, say the results may
change the standard of care for the disease. Patients received a combination of highdose chemotherapy with immune therapy, rather than the standard combination of
chemotherapy with whole-brain radiotherapy. The new approach was less toxic and
worked better, with the majority of patients still alive five years following treatment. The
lymphoma-free survival of patients with this form of cancer was doubled compared to
the lymphoma-free survival in previous trials involving brain radiotherapy, says UCSF
oncologist James Rubenstein, MD, PhD, who led the study. He and his team also found a
gene that, depending on how much of it is present, is a biomarker for potentially predicting
treatment outcomes – a discovery that may enable personalized care.
Harold Varmus and J. Michael Bishop win
the Nobel Prize for their discovery of
cancer-causing oncogenes
Nancy White Gamble’s life changed in 2008, when she was diagnosed with acute promyelocytic
leukemia, a rare form of blood cancer. Within days, Gamble, who lives in Napa, Calif., met with
UCSF’s Lloyd Damon, MD, director of hematologic malignancies and bone marrow transplant.
Although the treatment that followed was harrowing, Gamble survived. In remission five years
later, she attributes much of her survival not only to the excellent care she received at UCSF,
but also to the hope Damon instilled in her. “He threw me a life preserver,” Gamble recalls,
“and all I had to do was grab it.” To show her gratitude, Gamble made a pledge to create the
Nancy White Gamble Hematologic-Malignancies Endowment. The endowment will support an
annual fellowship for future Bone Marrow Transplantation (BMT) physicians. Training the next
generation is critical, says Damon, who holds the Robert O. and Angela W. Johnson Endowed
Chair of Hematopoetic Malignancies. While the need for BMT continues to grow, the number of
doctors entering the field has not. The endowment will provide much-needed funding to help
reverse this trend.
Researchers have discovered that melanoma cells that develop resistance to the
anti-cancer drug vemurafenib (marketed as Zelboraf) also develop addiction to
the drug – an observation with potential implications for patients with late-stage
disease. The team, based at UCSF, the Novartis Institutes for Biomedical Research
in Emeryville, Calif., and University Hospital Zurich, found that as a result of their
addiction, cells use vemurafenib to spur the growth of rapidly progressing, deadly, and
drug-resistant tumors. However, adjusting the dosing and introducing an on-again,
off-again treatment schedule prolonged the life of mice with melanoma, says co-lead
researcher Martin McMahon, PhD, the Efim Guzik Distinguished Professor of Cancer
Biology. A similar approach may extend the effectiveness of the drug for people – an
idea that awaits testing in clinical trials. Melanoma is the most aggressive type of skin
cancer. In 2012 alone, an estimated 76,250 people in the US were newly diagnosed with
it, while 9,180 people died from the disease.
Director, UCSF Helen Diller Family Comprehensive Cancer Center
E. Dixon Heise Distinguished Professor in Oncology
David A. Wood Distinguished Professor of Tumor Biology and Cancer Research
Cancer Center
Milestones
Blood Cancer LifeLine Flows Both Ways
Lloyd Damon with Nancy White Gamble
Interrupting Treatment Prolongs Life
Frank McCormick, PhD, FRS, DSc (Hon)
1989
Mark Moasser
(left) with
Sisi and Bert Damner
Diagnosed with breast cancer in 2010, Sisi Damner interviewed many physicians before she
found Mark M. Moasser, MD, a breast care specialist at the UCSF Carol Franc Buck Breast
Care Center. “He’s an authority in his field and he’s also a good listener,” Damner says. “The
two don’t always go together.” Moasser is one of several UCSF physician-scientists working
at the interface of the clinical and scientific realms. He credits the patients he cares for in the
oncology clinic for motivating his research. “Our larger vision is to find curative therapies
for cancers driven by the HER2/neu oncogene, which account for 20 to 25 percent of breast
cancers as well as many other cancers,” he says. Three years later, Damner is busy traveling
and taking up new hobbies. In gratitude, she and her husband, Bert, named the UCSF breast
cancer program a beneficiary of their charitable remainder trust. “We can’t help but want to
support UCSF’s research into breast cancer,” Damner says, “the findings from which have the
potential to make a difference to cancer patients and their families worldwide.”
1998
First became an NCI-designated
comprehensive cancer center, an honor
maintained through today
2007
Cancer Center renamed the UCSF Helen Diller Family
Comprehensive Cancer Center in tribute to the family’s
commitment to improving lives around the world
Partnering to fight brain cancer
Ashley Dabbiere is mother to four active young children, so when she noticed a creeping
forgetfulness she attributed it to “baby brain.” But a 2012 MRI revealed a tumor occupying
more than half of her brain’s frontal lobe. “My husband and I immediately started doing research
because we wanted to find the best brain surgeon in the world. We quickly settled on Dr.
Berger,” says Ashley, who lives outside Washington, DC. Mitchel Berger, MD, is the Berthold
and Belle N. Guggenhime Professor and director of the Brain Tumor Research Center at UCSF.
“The Dabbieres took ownership of the problem in a way that they could be part of the solution,”
says Berger. The couple made two unrestricted gifts toward Berger’s research, which he is
using to investigate how low grade slow-growing gliomas (the type Ashley has) evolve into high
grade fast-growing tumors. “We can’t do what Dr. Berger does,” says Alan. “What we can do
is build awareness and provide funding to help him find better cures for my wife and a lot of
people. We are glad to partner with UCSF.”
Mitch Berger (left) with
Ashley and Alan Dabbiere
2009
Helen Diller Family Cancer Research Building opens
at Mission Bay, bringing investigators into the
center of a powerful basic research community
2013
Elizabeth Blackburn wins the Nobel Prize for her codiscovery of telomeres and the enzyme telomerase,
which have implications for cancer therapies
U.S. News & World Report ranked UCSF Medical Center as
the 7th best hospital in the nation, 1st among California, and
among the top in the nation for the 8th consecutive year
2015
UCSF Bakar Cancer Hospital at
Mission Bay slated to open to patients
financial highlights
Visionary Circle
Honor Roll
of Donors
Lifetime Giving of $1 Million and Above
Restricted
$27,754,549
7.1%
e.g., to a specific program
Unrestricted
$2,115,236
92.9%
e.g., General Fund
Total$29,869,785
1%
Sources of Philanthropic Support
To cancer programs at UCSF for the fiscal year
ending June 30, 2013
Individuals
$15,935,803
Foundations and
Family Foundations
Corporations
15%
Other Organizations
$9,198,295
53%
31%
$4,559,126
$176,561
Total$29,869,785
Sources of
Philanthropic Support
$45,828,912
$42,437,012
$36,491,451
Yearly summary for fiscal years 2009–2013
$31,913,032
$29,869,785
Other Organizations
Individuals
Foundations and Family Foundations
Corporations
2009
2010
2011
2012
2013
Anonymous (18)
Accelerate Brain Cancer Cure, Inc.
The Bonnie J. Addario Lung
Cancer Foundation
Estate of Edward S. Ageno
American Association for
Cancer Research
American Brain Tumor Association
American Cancer Society
American Cancer Society
California Division
American Society of Clinical Oncology
Estate of Stanford W. Ascherman
The Atlantic Philanthropies
Martha and H. Brewster Atwater
Roma M. Auerback
Avon Foundation
Ayco Charitable Foundation
Lynne and Marc R. Benioff
Theodora B. Betz Foundation
Bionovo, Inc.
Jane Bishop *
Frances F. Bowes
William K. Bowes, Jr. Foundation
The Breast Cancer Research
Foundation
Linda and Neill H. Brownstein
Carol Franc Buck
Eva Benson Buck Charitable Trust D
Estate of Hildur V. Bullerwell
Christine and Steven A. Burd
Frank A. Campini Foundation
Cancer Research Institute
Champion Charities
Chevron U.S.A. Inc.
Estate of Ruth M. DeBernardi
Donna M. and Kenneth T. Derr
Helen Diller Family Foundation
Ann H. and L. John Doerr III
Estate of Volker Dolch
Carol P. and Michael I. Dollinger
The Dougherty Family Foundation
Greg Dougherty
Nancy Dougherty
Joseph Drown Foundation
The Ellison Medical Foundation
Anne and Jason Farber
Foundation, Inc.
Estate of Condina J. Ferro
Fidelity Investments Charitable
Gift Fund
Fisher Families
Joseph H. Friend *
Susan M. Geck *
Genentech, Inc.
The Goldhirsh Foundation, Inc.
Richard and Rhoda Goldman Fund
Richard N. Goldman *
Nancy and Stephen Grand
Guzik Foundation
Mimi and Peter Haas Fund
Estate of E. Dixon Heise
Informed Medical Decisions
Foundation
Pepper and Michael Jackson
Joan and Irwin M. Jacobs
Jewish Community Federation of
San Francisco, the Peninsula,
Marin and Sonoma Counties
Jewish Community Foundation
Jewish Community Foundation
of San Diego
Kalmanovitz Charitable Foundation
Kazan, McClain, Abrams,
Fernandez, Lyons, Greenwood, Harley & Oberman Foundation
Kirk Kerkorian
Alison and Arthur H. Kern
Gwen M. and John A. Kerner
Sidney Kimmel Foundation for
Cancer Research
The Susan G. Komen Breast
Cancer Foundation
Deepa N. Iyengar and
Ashok Krishnamurthi
Mary V. Lester and W. Howard Lester *
The Leukemia and Lymphoma
Society
The Lincy Foundation
The Listwin Family Foundation
Edmund & Jeannik Littlefield
Foundation
Jeannik Mequet Littlefield *
Marin Community Foundation
Lucille P. Markey Charitable Trust
Estate of Alicia McEvoy
Estate of Claire C. McEvoy
Estate of Jay D. McEvoy
Nan Tucker McEvoy
Nion T. McEvoy
The Minneapolis Foundation
Estate of Frederick S. Moody
Betty I. and Gordon E. Moore
Mount Zion Health Fund
Multiple Myeloma Research
Foundation
National Brain Tumor Society
Merillyn J. Noren
Susan and William E. Oberndorf
The Bernard Osher Foundation
Pediatric Brain Tumor Foundation
Jeffrey and Karen Peterson
Family Foundation
Estate of Kathleen Mahoney Plant
Catherine H. and Michael H. Podell
Helen* and Sol* Price
Prospect Creek Foundation
Prostate Cancer Foundation
Radiology Research and
Education Foundation
Estate of Mary Ann Radovich
George R. Roberts
Estate of Mario J. Rocca
Arthur and Toni Rembe Rock
Rombauer Family
Damon Runyon Cancer
Research Foundation
The Safeway Foundation
Safeway, Inc.
The San Francisco Foundation
San Francisco General
Hospital Foundation
Schwab Charitable Fund
Bernard Lee Schwartz
Foundation, Inc.
Estate of Jack Douglas Shand
William Siebrandt
Silicon Valley Community Foundation
Sandra Lloyd and W. Douglass Smith
Elle and Paul H. Stephens
Alexander and Margaret
Stewart Trust
The V Foundation for
Cancer Research
Eddi and Wendell Van Auken
Vanguard Charitable
Endowment Program
Angela C. Wang
Dana A. Corvin and Harris Weinberg
Robert K. Werbe *
Diana S. * and Herschel S. *
Zackheim
*deceased
2012–2013
Address service requested
To cancer programs at UCSF for the fiscal year
ending June 30, 2013
0906
University Development and Alumni Relations
UCSF Box 0248
San Francisco, CA 94143-0248
Allocation of Philanthropic Support
Possibilities for Partnership
To learn more about our cancer center priorities, please contact:
Suzanne Teer, Executive Director of Development
415/476-3622
[email protected]
UCSF Box 0248, San Francisco, CA 94143-0248
support.ucsf.edu
Produced by the UCSF Office of University Development and Alumni Relations
Managing Editor: Kate Volkman Oakes Design: Pamela Kato
Writers: Jason Bardi, Elizabeth Fernandez, Susan Godstone, Photographers: Steve Babuljak, Noah Berger, Cindy Chew,
Samantha Jang, Kate Volkman Oakes Elisabeth Fall, Susan Godstone, Carmen Holt
© 2013 The Regents of the University of California
We’ve Gone Green!
Please visit us online to view a complete list of FY12-13 donors: support.ucsf.edu/cancer/honor-roll
financial highlights
Visionary Circle
Honor Roll
of Donors
Lifetime Giving of $1 Million and Above
Restricted
$27,754,549
7.1%
e.g., to a specific program
Unrestricted
$2,115,236
92.9%
e.g., General Fund
Total$29,869,785
1%
Sources of Philanthropic Support
To cancer programs at UCSF for the fiscal year
ending June 30, 2013
Individuals
$15,935,803
Foundations and
Family Foundations
Corporations
15%
Other Organizations
$9,198,295
53%
31%
$4,559,126
$176,561
Total$29,869,785
Sources of
Philanthropic Support
$45,828,912
$42,437,012
$36,491,451
Yearly summary for fiscal years 2009–2013
$31,913,032
$29,869,785
Other Organizations
Individuals
Foundations and Family Foundations
Corporations
2009
2010
2011
2012
2013
Anonymous (18)
Accelerate Brain Cancer Cure, Inc.
The Bonnie J. Addario Lung
Cancer Foundation
Estate of Edward S. Ageno
American Association for
Cancer Research
American Brain Tumor Association
American Cancer Society
American Cancer Society
California Division
American Society of Clinical Oncology
Estate of Stanford W. Ascherman
The Atlantic Philanthropies
Martha and H. Brewster Atwater
Roma M. Auerback
Avon Foundation
Ayco Charitable Foundation
Lynne and Marc R. Benioff
Theodora B. Betz Foundation
Bionovo, Inc.
Jane Bishop *
Frances F. Bowes
William K. Bowes, Jr. Foundation
The Breast Cancer Research
Foundation
Linda and Neill H. Brownstein
Carol Franc Buck
Eva Benson Buck Charitable Trust D
Estate of Hildur V. Bullerwell
Christine and Steven A. Burd
Frank A. Campini Foundation
Cancer Research Institute
Champion Charities
Chevron U.S.A. Inc.
Estate of Ruth M. DeBernardi
Donna M. and Kenneth T. Derr
Helen Diller Family Foundation
Ann H. and L. John Doerr III
Estate of Volker Dolch
Carol P. and Michael I. Dollinger
The Dougherty Family Foundation
Greg Dougherty
Nancy Dougherty
Joseph Drown Foundation
The Ellison Medical Foundation
Anne and Jason Farber
Foundation, Inc.
Estate of Condina J. Ferro
Fidelity Investments Charitable
Gift Fund
Fisher Families
Joseph H. Friend *
Susan M. Geck *
Genentech, Inc.
The Goldhirsh Foundation, Inc.
Richard and Rhoda Goldman Fund
Richard N. Goldman *
Nancy and Stephen Grand
Guzik Foundation
Mimi and Peter Haas Fund
Estate of E. Dixon Heise
Informed Medical Decisions
Foundation
Pepper and Michael Jackson
Joan and Irwin M. Jacobs
Jewish Community Federation of
San Francisco, the Peninsula,
Marin and Sonoma Counties
Jewish Community Foundation
Jewish Community Foundation
of San Diego
Kalmanovitz Charitable Foundation
Kazan, McClain, Abrams,
Fernandez, Lyons, Greenwood, Harley & Oberman Foundation
Kirk Kerkorian
Alison and Arthur H. Kern
Gwen M. and John A. Kerner
Sidney Kimmel Foundation for
Cancer Research
The Susan G. Komen Breast
Cancer Foundation
Deepa N. Iyengar and
Ashok Krishnamurthi
Mary V. Lester and W. Howard Lester *
The Leukemia and Lymphoma
Society
The Lincy Foundation
The Listwin Family Foundation
Edmund & Jeannik Littlefield
Foundation
Jeannik Mequet Littlefield *
Marin Community Foundation
Lucille P. Markey Charitable Trust
Estate of Alicia McEvoy
Estate of Claire C. McEvoy
Estate of Jay D. McEvoy
Nan Tucker McEvoy
Nion T. McEvoy
The Minneapolis Foundation
Estate of Frederick S. Moody
Betty I. and Gordon E. Moore
Mount Zion Health Fund
Multiple Myeloma Research
Foundation
National Brain Tumor Society
Merillyn J. Noren
Susan and William E. Oberndorf
The Bernard Osher Foundation
Pediatric Brain Tumor Foundation
Jeffrey and Karen Peterson
Family Foundation
Estate of Kathleen Mahoney Plant
Catherine H. and Michael H. Podell
Helen* and Sol* Price
Prospect Creek Foundation
Prostate Cancer Foundation
Radiology Research and
Education Foundation
Estate of Mary Ann Radovich
George R. Roberts
Estate of Mario J. Rocca
Arthur and Toni Rembe Rock
Rombauer Family
Damon Runyon Cancer
Research Foundation
The Safeway Foundation
Safeway, Inc.
The San Francisco Foundation
San Francisco General
Hospital Foundation
Schwab Charitable Fund
Bernard Lee Schwartz
Foundation, Inc.
Estate of Jack Douglas Shand
William Siebrandt
Silicon Valley Community Foundation
Sandra Lloyd and W. Douglass Smith
Elle and Paul H. Stephens
Alexander and Margaret
Stewart Trust
The V Foundation for
Cancer Research
Eddi and Wendell Van Auken
Vanguard Charitable
Endowment Program
Angela C. Wang
Dana A. Corvin and Harris Weinberg
Robert K. Werbe *
Diana S. * and Herschel S. *
Zackheim
*deceased
2012–2013
Address service requested
To cancer programs at UCSF for the fiscal year
ending June 30, 2013
0906
University Development and Alumni Relations
UCSF Box 0248
San Francisco, CA 94143-0248
Allocation of Philanthropic Support
Possibilities for Partnership
To learn more about our cancer center priorities, please contact:
Suzanne Teer, Executive Director of Development
415/476-3622
[email protected]
UCSF Box 0248, San Francisco, CA 94143-0248
support.ucsf.edu
Produced by the UCSF Office of University Development and Alumni Relations
Managing Editor: Kate Volkman Oakes Design: Pamela Kato
Writers: Jason Bardi, Elizabeth Fernandez, Susan Godstone, Photographers: Steve Babuljak, Noah Berger, Cindy Chew,
Samantha Jang, Kate Volkman Oakes Elisabeth Fall, Susan Godstone, Carmen Holt
© 2013 The Regents of the University of California
We’ve Gone Green!
Please visit us online to view a complete list of FY12-13 donors: support.ucsf.edu/cancer/honor-roll
financial highlights
Visionary Circle
Honor Roll
of Donors
Lifetime Giving of $1 Million and Above
Restricted
$27,754,549
7.1%
e.g., to a specific program
Unrestricted
$2,115,236
92.9%
e.g., General Fund
Total$29,869,785
1%
Sources of Philanthropic Support
To cancer programs at UCSF for the fiscal year
ending June 30, 2013
Individuals
$15,935,803
Foundations and
Family Foundations
Corporations
15%
Other Organizations
$9,198,295
53%
31%
$4,559,126
$176,561
Total$29,869,785
Sources of
Philanthropic Support
$45,828,912
$42,437,012
$36,491,451
Yearly summary for fiscal years 2009–2013
$31,913,032
$29,869,785
Other Organizations
Individuals
Foundations and Family Foundations
Corporations
2009
2010
2011
2012
2013
Anonymous (18)
Accelerate Brain Cancer Cure, Inc.
The Bonnie J. Addario Lung
Cancer Foundation
Estate of Edward S. Ageno
American Association for
Cancer Research
American Brain Tumor Association
American Cancer Society
American Cancer Society
California Division
American Society of Clinical Oncology
Estate of Stanford W. Ascherman
The Atlantic Philanthropies
Martha and H. Brewster Atwater
Roma M. Auerback
Avon Foundation
Ayco Charitable Foundation
Lynne and Marc R. Benioff
Theodora B. Betz Foundation
Bionovo, Inc.
Jane Bishop *
Frances F. Bowes
William K. Bowes, Jr. Foundation
The Breast Cancer Research
Foundation
Linda and Neill H. Brownstein
Carol Franc Buck
Eva Benson Buck Charitable Trust D
Estate of Hildur V. Bullerwell
Christine and Steven A. Burd
Frank A. Campini Foundation
Cancer Research Institute
Champion Charities
Chevron U.S.A. Inc.
Estate of Ruth M. DeBernardi
Donna M. and Kenneth T. Derr
Helen Diller Family Foundation
Ann H. and L. John Doerr III
Estate of Volker Dolch
Carol P. and Michael I. Dollinger
The Dougherty Family Foundation
Greg Dougherty
Nancy Dougherty
Joseph Drown Foundation
The Ellison Medical Foundation
Anne and Jason Farber
Foundation, Inc.
Estate of Condina J. Ferro
Fidelity Investments Charitable
Gift Fund
Fisher Families
Joseph H. Friend *
Susan M. Geck *
Genentech, Inc.
The Goldhirsh Foundation, Inc.
Richard and Rhoda Goldman Fund
Richard N. Goldman *
Nancy and Stephen Grand
Guzik Foundation
Mimi and Peter Haas Fund
Estate of E. Dixon Heise
Informed Medical Decisions
Foundation
Pepper and Michael Jackson
Joan and Irwin M. Jacobs
Jewish Community Federation of
San Francisco, the Peninsula,
Marin and Sonoma Counties
Jewish Community Foundation
Jewish Community Foundation
of San Diego
Kalmanovitz Charitable Foundation
Kazan, McClain, Abrams,
Fernandez, Lyons, Greenwood, Harley & Oberman Foundation
Kirk Kerkorian
Alison and Arthur H. Kern
Gwen M. and John A. Kerner
Sidney Kimmel Foundation for
Cancer Research
The Susan G. Komen Breast
Cancer Foundation
Deepa N. Iyengar and
Ashok Krishnamurthi
Mary V. Lester and W. Howard Lester *
The Leukemia and Lymphoma
Society
The Lincy Foundation
The Listwin Family Foundation
Edmund & Jeannik Littlefield
Foundation
Jeannik Mequet Littlefield *
Marin Community Foundation
Lucille P. Markey Charitable Trust
Estate of Alicia McEvoy
Estate of Claire C. McEvoy
Estate of Jay D. McEvoy
Nan Tucker McEvoy
Nion T. McEvoy
The Minneapolis Foundation
Estate of Frederick S. Moody
Betty I. and Gordon E. Moore
Mount Zion Health Fund
Multiple Myeloma Research
Foundation
National Brain Tumor Society
Merillyn J. Noren
Susan and William E. Oberndorf
The Bernard Osher Foundation
Pediatric Brain Tumor Foundation
Jeffrey and Karen Peterson
Family Foundation
Estate of Kathleen Mahoney Plant
Catherine H. and Michael H. Podell
Helen* and Sol* Price
Prospect Creek Foundation
Prostate Cancer Foundation
Radiology Research and
Education Foundation
Estate of Mary Ann Radovich
George R. Roberts
Estate of Mario J. Rocca
Arthur and Toni Rembe Rock
Rombauer Family
Damon Runyon Cancer
Research Foundation
The Safeway Foundation
Safeway, Inc.
The San Francisco Foundation
San Francisco General
Hospital Foundation
Schwab Charitable Fund
Bernard Lee Schwartz
Foundation, Inc.
Estate of Jack Douglas Shand
William Siebrandt
Silicon Valley Community Foundation
Sandra Lloyd and W. Douglass Smith
Elle and Paul H. Stephens
Alexander and Margaret
Stewart Trust
The V Foundation for
Cancer Research
Eddi and Wendell Van Auken
Vanguard Charitable
Endowment Program
Angela C. Wang
Dana A. Corvin and Harris Weinberg
Robert K. Werbe *
Diana S. * and Herschel S. *
Zackheim
*deceased
2012–2013
Address service requested
To cancer programs at UCSF for the fiscal year
ending June 30, 2013
0906
University Development and Alumni Relations
UCSF Box 0248
San Francisco, CA 94143-0248
Allocation of Philanthropic Support
Possibilities for Partnership
To learn more about our cancer center priorities, please contact:
Suzanne Teer, Executive Director of Development
415/476-3622
[email protected]
UCSF Box 0248, San Francisco, CA 94143-0248
support.ucsf.edu
Produced by the UCSF Office of University Development and Alumni Relations
Managing Editor: Kate Volkman Oakes Design: Pamela Kato
Writers: Jason Bardi, Elizabeth Fernandez, Susan Godstone, Photographers: Steve Babuljak, Noah Berger, Cindy Chew,
Samantha Jang, Kate Volkman Oakes Elisabeth Fall, Susan Godstone, Carmen Holt
© 2013 The Regents of the University of California
We’ve Gone Green!
Please visit us online to view a complete list of FY12-13 donors: support.ucsf.edu/cancer/honor-roll